The global uveitis treatment market size reached US$ 1.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 4.3% during 2023-2028.
Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of eye and sensitivity to light. Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines. These therapeutics are directed toward reducing inflammation, alleviating pain, preventing further tissue damage and restoring vision loss and can be used to treat conditions, including anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.
The increasing prevalence of optical infections and chronic eye disorders across the globe represents one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy and autoimmune and inflammatory disorders. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness regarding the available treatment alternatives for managing uveitis has resulted in a significant increase in the demand for corticosteroid treatments among patients and healthcare providers. Additionally, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors. These biological therapeutic agents are effective in the treatment of chronic uveitis and are administered as subcutaneous injections. Other factors, including the implementation of favorable initiatives by the governments to promote public health, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global uveitis treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type, disease type, cause and distribution channel.
Breakup by Treatment Type:
Breakup by Disease Type:
Breakup by Cause:
Breakup by Distribution Channel:
Breakup by Region:
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.
Base Year of the Analysis
Treatment Type, Disease Type, Cause, Distribution Channel, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global uveitis treatment market was valued at US$ 1.6 Billion in 2022.
We expect the global uveitis treatment market to exhibit a CAGR of 4.3% during 2023-2028.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment for uveitis treatment to reduce the risk of the coronavirus infections upon hospital visits and interaction with medical equipment and healthcare professionals.
The rising prevalence of optical infections and chronic eye disorders, along with the growing consumer awareness towards the available treatment alternatives for managing uveitis, is primarily driving the global uveitis treatment market.
Based on the treatment type, the global uveitis treatment market has been divided into corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. Among these, corticosteroids exhibit a clear dominance in the market.
Based on the disease type, the global uveitis treatment market can be categorized into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. Currently, anterior uveitis accounts for the majority of the total market share.
Based on the cause, the global uveitis treatment market has been segregated into infectious and non-infectious, where non-infectious holds the largest market share.
Based on the distribution channel, the global uveitis treatment market can be bifurcated into hospital pharmacies, retail pharmacies, online pharmacies, and others. Currently, retail pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global uveitis treatment market include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.